| Trial of tocilizumab in giant-cell arteritis JH Stone, K Tuckwell, S Dimonaco, M Klearman, M Aringer, D Blockmans, ... New England Journal of Medicine 377 (4), 317-328, 2017 | 1299 | 2017 |
| Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis C Gabay, IB McInnes, A Kavanaugh, K Tuckwell, M Klearman, J Pulley, ... Annals of the rheumatic diseases 75 (10), 1806-1812, 2016 | 157 | 2016 |
| Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial IO Rosas, G Diaz, RL Gottlieb, SM Lobo, P Robinson, BD Hunter, ... Intensive care medicine 47, 1258-1270, 2021 | 118 | 2021 |
| Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case–control analysis JC Wilson, K Sarsour, N Collinson, K Tuckwell, D Musselman, ... Seminars in arthritis and rheumatism 46 (6), 819-827, 2017 | 106 | 2017 |
| Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis MS Broder, K Sarsour, E Chang, N Collinson, K Tuckwell, P Napalkov, ... Seminars in Arthritis and Rheumatism 46 (2), 246-252, 2016 | 106 | 2016 |
| Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor fenebrutinib (GDC‐0853) in systemic lupus erythematosus: results of a phase II … D Isenberg, R Furie, NS Jones, P Guibord, J Galanter, C Lee, A McGregor, ... Arthritis & Rheumatology 73 (10), 1835-1846, 2021 | 100 | 2021 |
| Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial S Cohen, K Tuckwell, TR Katsumoto, R Zhao, J Galanter, C Lee, J Rae, ... Arthritis & Rheumatology 72 (9), 1435-1446, 2020 | 96 | 2020 |
| Glucocorticoid dosages and Acute‐Phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab JH Stone, K Tuckwell, S Dimonaco, M Klearman, M Aringer, D Blockmans, ... Arthritis & Rheumatology 71 (8), 1329-1338, 2019 | 92 | 2019 |
| Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial K Tuckwell, N Collinson, S Dimonaco, M Klearman, D Blockmans, ... Seminars in arthritis and rheumatism 46 (5), 657-664, 2017 | 83 | 2017 |
| Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK S Gale, JC Wilson, J Chia, H Trinh, K Tuckwell, N Collinson, S Dimonaco, ... Rheumatology and therapy 5, 327-340, 2018 | 71 | 2018 |
| Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis JC Wilson, K Sarsour, N Collinson, K Tuckwell, D Musselman, ... Seminars in arthritis and rheumatism 46 (5), 650-656, 2017 | 57 | 2017 |
| Subunit assembly for DNA cleavage by restriction endonuclease SgrAI LE Daniels, KM Wood, DJ Scott, SE Halford Journal of molecular biology 327 (3), 579-591, 2003 | 51 | 2003 |
| Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial JH Stone, K Tuckwell, S Dimonaco, M Klearman, M Aringer, D Blockmans, ... Arthritis & Rheumatology 68, 2016 | 49 | 2016 |
| Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial V Strand, S Dimonaco, K Tuckwell, M Klearman, N Collinson, JH Stone Arthritis Research & Therapy 21, 1-9, 2019 | 38 | 2019 |
| Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis P Welsh, K Tuckwell, IB McInnes, N Sattar Atherosclerosis 254, 167-171, 2016 | 30 | 2016 |
| Long-range communications between DNA sites by the dimeric restriction endonuclease SgrAI KM Wood, LE Daniels, SE Halford Journal of molecular biology 350 (2), 240-253, 2005 | 28 | 2005 |
| Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials V Strand, M Michalska, C Birchwood, J Pei, K Tuckwell, R Finch, C Gabay, ... RMD open 3 (2), e000496, 2017 | 21 | 2017 |
| Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis V Strand, M Michalska, C Birchwood, J Pei, K Tuckwell, R Finch, AJ Kivitz, ... RMD open 4 (1), e000602, 2018 | 20 | 2018 |
| Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: analyses of tocilizumab clinical trials and claims data S Gale, H Trinh, K Tuckwell, N Collinson, JH Stone, K Sarsour, J Pei, ... Rheumatology and Therapy 6, 77-88, 2019 | 19 | 2019 |
| Development and implementation of a double‐blind corticosteroid‐tapering regimen for a clinical trial N Collinson, K Tuckwell, F Habeck, M Chapman, M Klearman, JH Stone International Journal of Rheumatology 2015 (1), 589841, 2015 | 19 | 2015 |
Daniel BlockmansHoogleraar Geneeskunde在 uzleuven.be 的电子邮件经过验证
